Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CODX vs BMRA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CODX Captures Overall Composite Edge (51.6 HOLD vs 44.5 HOLD), While BMRA Leads 3–2 on Growth & Valuation Pillars
CODX Overall Winner
6-Pillar Tally: CODX 2 – 3 BMRA (1 Tie)
Matrix Metrics: CODX 5 – 4 BMRA
As of Nov 16, 2026, Co-Diagnostics, Inc. (CODX) captures the overall head-to-head institutional edge over Biomerica Inc (BMRA) on higher Unified Composite conviction (51.6/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples, Growth & Scale), while BMRA wins 3–2 across the 6-pillar growth and valuation breakdown. CODX trades at $0.23 (15.4x Forward P/E, -3415.8% operating margin) versus BMRA at $1.33 (N/M Forward P/E, -125.2% operating margin).
- Growth vs. Quality Trade-Off: CODX earns the overall head-to-head edge with a stronger Unified Composite Score (51.6/100 HOLD vs. BMRA 44.5/100 HOLD) and 2.92β · 148% Vol risk profile, whereas BMRA leads top-line expansion (-8.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: CODX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About CODX vs BMRA
CODX
Head-to-Head Winner
Co-Diagnostics, Inc. Common Stock
$0.23
-12.26% 1D
Market Cap
$2.3M
TTM Revenue
$858,888
Forward P/E
15.4x
Beta / 30D Vol
2.92β · 148% Vol
Unified Composite Score
51.6
HOLD
Tech 55.0
Fund 54.0
Flow 66.0
Mom 40.0
Weinstein Technical Phase
Markdown · Sell / avoid
BMRA
Biomerica Inc
$1.33
-2.32% 1D
Market Cap
$6.0M
TTM Revenue
$4.3M
Forward P/E
N/M
Beta / 30D Vol
0.67β · 62% Vol
Unified Composite Score
44.5
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (CODX 2 – 3 BMRA)
1. Valuation Multiples
CODX
Forward P/E
15.4x
N/M
Trailing P/E
15.4x
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
1.1x
2. Growth & Scale
CODX
Revenue Growth (YoY)
+94.6%
-8.3%
Earnings Growth (YoY)
+30.8%
+0.0%
TTM Revenue (USD)
$858,888
$4.3M
Market Cap
$2.3M
$6.0M
3. Profitability & Quality
BMRA
Gross Margin
20.3%
0.9%
Operating Margin
-3415.8%
-125.2%
Net Profit Margin
0.0%
-115.5%
Return on Equity (ROE)
-192.8%
-113.8%
4. Balance Sheet & Cash Flow
BMRA
Cash Generation (TTM)
-$28M EBITDA
-$3.2M
Cash Flow Margin
N/A
-73.5%
Net Cash / Leverage
$6.2M Net Cash
$1.1M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BMRA
Options Structure Phase
BREAKDOWN
UNCLASSIFIED
Current IV / %ile
270.2% (50th %ile)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
DISTRIBUTION · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: CODX (5) vs BMRA (4)| Institutional Metric | CODX | BMRA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.3M | $6.0M | Tie | |
| Trailing P/E Ratio | 15.4x | N/M | CODX | |
| Forward P/E Ratio | 15.4x | N/M | CODX | |
| Revenue Growth (YoY) | +94.6% | -8.3% | CODX | |
| Operating Margin (TTM) | -3415.8% | -125.2% | BMRA | |
| Net Profit Margin | 0.0% | -115.5% | CODX | |
| Return on Equity (ROE) | -192.8% | -113.8% | BMRA | |
| 52-Week Range Position | 0% ($0–$14) | 4% ($1–$3) | BMRA | |
| Beta / 30D Volatility | 2.92β · 148% Vol | 0.67β · 62% Vol | BMRA | |
| Unified Institutional Score | 51.6 / 100 (HOLD) | 44.5 / 100 (HOLD) | CODX | |
| Trailing 12M Revenue (USD) | $858,888 | $4.3M | Scale | |
| Gross Profit Margin (TTM) | 20.3% | 0.9% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 1.1x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$28M EBITDA ($6.2M Net Cash) | -$3.2M ($1.1M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
BMRA +37.12 pp
3M Horizon
BMRA +65.02 pp
6M Horizon
BMRA +42.48 pp
1Y Horizon
CODX +7.85 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CODX Revenue | BMRA Revenue | CODX Op. Margin | BMRA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $0M | $10M | -2741.6% | -46.4% | BMRA |
| FY2020 | $70M | $10M | 55.9% | -41.0% | CODX |
| FY2021 | $100M | $10M | 47.1% | -104.2% | CODX |
| FY2022 | $30M | $20M | -78.8% | -24.0% | BMRA |
| FY2023 | $10M | $10M | -626.9% | -135.3% | BMRA |
| FY2024 | $0M | $10M | -1023.7% | -117.6% | BMRA |
| FY2025 | $0M | $10M | -8058.8% | -96.7% | BMRA |
| FY2026 | N/A | $0M | N/A | -119.5% | BMRA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
CODX
BREAKDOWN
Current IV
270.2%
IV Percentile
50th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact CODX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BMRA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
CODX Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BMRA Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ CODX vs BMRA Key Questions & Quantitative Answers
As of Nov 16, 2026, Co-Diagnostics, Inc. (CODX) captures the overall head-to-head institutional edge over Biomerica Inc (BMRA) on higher Unified Composite conviction (51.6/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples, Growth & Scale), while BMRA wins 3–2 across the 6-pillar growth and valuation breakdown. CODX trades at $0.23 (15.4x Forward P/E, -3415.8% operating margin) versus BMRA at $1.33 (N/M Forward P/E, -125.2% operating margin). Growth vs. Quality Trade-Off: CODX earns the overall head-to-head edge with a stronger Unified Composite Score (51.6/100 HOLD vs. BMRA 44.5/100 HOLD) and 2.92β · 148% Vol risk profile, whereas BMRA leads top-line expansion (-8.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CODX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CODX leads the Growth & Scale pillar: CODX posts +94.6% YoY revenue growth and +30.8% YoY earnings growth on $858,888 TTM revenue (20.3% gross margin, -3415.8% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CODX cumulative revenue shifted -85.7% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, CODX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.
CODX screens cheaper on headline valuation multiples. CODX trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CODX (-192.8% ROE) versus BMRA (-113.8% ROE) capital efficiency.
In options market volatility and institutional positioning, CODX carries 270.2% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.92β · 148% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BMRA vs CODX · Reverse Pair
CODX vs APT
· Sector Peer
CODX vs VIR
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal